Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy

References

• SenterPDPotent antibody drug conjugates for cancer therapyCurr Opin Chem Biol200913323524419414278
   PubMed Web of Science ®Google Scholar
• TeicherBAChariRVJAntibody conjugate therapeutics: Challenges and potentialClin Cancer Res201117206389639722003066
   PubMed Web of Science ®Google Scholar
• CasiGNeriDAntibody-drug conjugates: Basic concepts, examples and future perspectivesJ Control Release2012161242242822306430
   PubMed Web of Science ®Google Scholar
• SieversELSenterPDAntibody-drug conjugates in cancer therapyAnnu Rev Med201364152923043493
   PubMed Web of Science ®Google Scholar
• AlleySCOkeleyNMSenterPDAntibody–drug conjugates: Targeted drug delivery for cancerCurr Opin Chem Biol201014452953720643572
   PubMed Web of Science ®Google Scholar
• SassoonIBlancVAntibody-drug conjugate (ADC) clinical pipeline: A reviewMethods Mol Biol2013104512723913138
   PubMedGoogle Scholar
• St BernardRZhengLLiuWWinerDAsaSLEzzatSFibroblast growth factor receptors as molecular targets in thyroid carcinomaEndocrinology200514631145115315564323
   PubMed Web of Science ®Google Scholar
• KnightsVCookSJDe-regulated FGF receptors as therapeutic targets in cancerPharmacol Ther2010125110511719874848
   PubMed Web of Science ®Google Scholar
• GavinePRMooneyLKilgourEAZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase familyCancer Res20127282045205622369928
   PubMed Web of Science ®Google Scholar
• HoHKYeoAHLKangTSChuaBTCurrent strategies for inhibiting FGFR activities in clinical applications: Opportunities, challenges and toxicological considerationsDrug Discov Today2014191516223932951
   PubMed Web of Science ®Google Scholar
• KachelPTrojanowiczBSekullaCPrenzelHDralleHHoang-VuCPhosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissueBMC Cancer201515111325971837
   PubMedGoogle Scholar
• TiseoMGelsominoFAlfieriRFGFR as potential target in the treatment of squamous non small cell lung cancerCancer Treat Rev201541652753925959741
   PubMed Web of Science ®Google Scholar
• ZhangXIbrahimiOAOlsenSKUmemoriHMohammadiMOrnitzDMReceptor specificity of the fibroblast growth factor family: The complete mammalian FGF familyJ Biol Chem200628123156941570016597617
   PubMed Web of Science ®Google Scholar
• FrieselRMaciagTInternalization and degradation of heparin binding growth factor-I by endothelial cellsBiochem Biophys Res Commun198815139579642451523
   PubMed Web of Science ®Google Scholar
• GriebTABurgessWHThe mitogenic activity of fibroblast growth factor-1 correlates with its internalization and limited proteolytic processingJ Cell Physiol2000184217118210867641
   PubMed Web of Science ®Google Scholar
• HaugstenEMMaleckiJBjørklundSMSOlsnesSWescheJUbiquitination of fibroblast growth factor receptor 1 is required for its intra-cellular sorting but not for its endocytosisMol Biol Cell20081983390340318480409
   PubMed Web of Science ®Google Scholar
• SzlachcicAPalaKZakrzewskaMJakimowiczPWiedlochaAOtlewskiJFGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiationInt J Nanomedicine201275915592723226697
   PubMed Web of Science ®Google Scholar
• ZakrzewskaMKrowarschDWiedlochaAOlsnesSOtlewskiJHighly stable mutants of human fibroblast growth factor-1 exhibit prolonged biological actionJ Mol Biol2005352486087516126225
   PubMed Web of Science ®Google Scholar
• CulajayJFBlaberSIKhuranaABlaberMThermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-lifeBiochemistry200039247153715810852713
   PubMed Web of Science ®Google Scholar
• GooznerMDrug approvals 2011: Focus on companion diagnosticsJ Natl Cancer Inst20121042848622215850
   PubMedGoogle Scholar
• PatelSKeohanMLSaifMWPhase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapyCancer2006107122881288717109446
   PubMed Web of Science ®Google Scholar
• RielyGJGadgeelSRothmanIA phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapyLung Cancer200755218118517092603
   PubMed Web of Science ®Google Scholar
• BanerjeeSWangZMohammadMSarkarFHMohammadRMEfficacy of selected natural products as therapeutic agents against cancerJ Nat Prod200871349249618302335
   PubMed Web of Science ®Google Scholar
• FranciscoJACervenyCGMeyerDLcAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityBlood200310241458146512714494
   PubMed Web of Science ®Google Scholar
• DoroninaSOTokiBETorgovMYDevelopment of potent monoclonal antibody auristatin conjugates for cancer therapyNat Biotechnol200321777878412778055
   PubMed Web of Science ®Google Scholar
• SutherlandMSKSandersonRJGordonKALysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugatesJ Biol Chem200628115105401054716484228
   PubMed Web of Science ®Google Scholar
• GerberHKung-SutherlandMStoneIPotent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomasBlood2009113184352436119147785
   PubMed Web of Science ®Google Scholar
• CopelandRAJiHHalfpennyAJThe structure of human acidic fibroblast growth factor and its interaction with heparinArch Biochem Biophys1991289153611716876
   PubMed Web of Science ®Google Scholar
• McLeskeySWDingIYFLippmanMEKernFGMDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligandsCancer Res19945425235307506125
   PubMed Web of Science ®Google Scholar
• SawyersCTargeted cancer therapyNature2004432701529429715549090
   PubMed Web of Science ®Google Scholar
• KluteKNackosETasakiSNguyenDPBanderNHTagawaSTMicrotubule inhibitor-based antibody-drug conjugates for cancer therapyOnco Targets Ther201472227223625506226
   PubMed Web of Science ®Google Scholar
• DubowchikGMFirestoneRAPadillaLCathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activityBioconjug Chem200213485586912121142
   PubMed Web of Science ®Google Scholar
• TokiBECervenyCGWahlAFSenterPDProtease-mediated fragmentation of p-amidobenzyl ethers: A new strategy for the activation of anticancer prodrugsJ Org Chem20026761866187211895404
   PubMed Web of Science ®Google Scholar
• DucryLStumpBAntibody−drug conjugates: Linking cytotoxic payloads to monoclonal antibodiesBioconjug Chem201021151319769391
   PubMed Web of Science ®Google Scholar
• DoroninaSOMendelsohnBABoveeTDEnhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicityBioconjug Chem200617111412416417259
   PubMed Web of Science ®Google Scholar
• GoldmacherVSAmphlettGWangLLazarACStatistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugatesMol Pharm20151261738174425635630
   PubMed Web of Science ®Google Scholar
• HamblettKJSenterPDChaceDFEffects of drug loading on the antitumor activity of a monoclonal antibody drug conjugateClin Cancer Res200410207063707015501986
   PubMed Web of Science ®Google Scholar
• SieversELSenterPDAntibody-drug conjugates in cancer therapyAnnu Rev Med201264152923043493
   PubMed Web of Science ®Google Scholar
• SochajAMŚwiderskaKWOtlewskiJCurrent methods for the synthesis of homogeneous antibody–drug conjugatesBiotechnol Adv2015336 Part 177578425981886
   PubMed Web of Science ®Google Scholar
• BurgessWHShaheenAMRaveraMJayeMDonohuePJWinklesJAPossible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residueJ Cell Biol19901115212921381699952
   PubMed Web of Science ®Google Scholar
• WongPHamptonBSzylobrytEGallagherAMJayeMBurgessWHAnalysis of putative heparin-binding domains of fibroblast growth factor-1: Using site-directed mutagenesis and peptide analoguesJ Biol Chem19952704325805258117592764
   PubMed Web of Science ®Google Scholar
• ChandlerLASosnowskiBAGreenleesLAukermanSLBairdAPierceGFPrevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell linesInt J Cancer199981345145810209961
   PubMed Web of Science ®Google Scholar
• HardingFASticklerMMRazoJDuBridgeRBThe immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regionsMAbs20102325626520400861
   PubMed Web of Science ®Google Scholar